Retatrutide (Eli Lilly’s investigational “triple agonist” weight-loss drug) has released more recent trial-news showing very large average weight loss—along with notable tolerability/side-effect concerns in some studies.[1][2]
Latest reported weight-loss results (news, May 2026)
- Eli Lilly reported that in a study of adults with obesity, participants had average weight loss of about 70.3 pounds over ~80 weeks, and 45% of patients on the 12 mg dose lost up to 30% of body weight.[2]
- Coverage also notes Lilly says results are comparable to bariatric surgery (as described in the reporting).[5]
Earlier major Phase 3 weight-loss headline (Dec 2025)
- In a 68-week Phase 3 study reported by media, the highest dose group that stayed on treatment reported about 28.7% weight loss, while all treated participants (including those who discontinued) averaged about 23.7% weight loss.[1]
- The same reporting highlighted that some participants stopped treatment due to side effects or losing “too much” weight.[1]
What to watch (because “results” can mean different things)
- Dose (often 8 mg vs 12 mg) and time on drug can change the headline number.[2][1]
- Discontinuation and adverse events can make “average weight loss” look different depending on whether analyses include people who stopped early.[1]
If you tell me what you mean by “latest” (e.g., this week only vs past 30 days) and which trial (obesity only vs obesity with knee osteoarthritis, etc.), I can narrow the news to the exact study and summarize the key endpoints.
Sources
The results of the drug are comparable to what is seen with bariatric surgery, according to Eli Lilly.
abcnews.comThe results of the drug are comparable to what is seen with bariatric surgery, according to Eli Lilly.
abcnews.comA new weight loss injection called retatrutide has shown remarkable results in…
www.diabetes.co.ukTransformation videos highlighting crazy weight loss journeys are taking over social media.
www.cbsnews.com"Retatrutide delivered powerful weight loss," Leerink Partners analyst David Risinger told investors on Thursday morning. The study's results are the latest signal that retatrutide may be the most effective weight-loss medication in development. As such, retatrutide is a highly anticipated addition to Lilly's (LLY) obesity portfolio, which already includes Zepbound, a weekly GLP-1/GIP shot, and Foundayo, a daily non-peptide GLP-1 pill. It is sometimes referred to as "triple G" because it...
www.morningstar.comParticipants of a phase III trial of investigational weight-loss drug retatrutide showed an average weight loss of almost 30% and “substantial” relief from knee osteoarthritis, manufacturer Eli Lilly and Company has announced. In a statement published on 11 December 2025, Eli Lilly reported results from its TRIUMPH-4 trial, which involved 445 participants aged over 18 […]
pharmaceutical-journal.comEli Lilly's next-gen obesity drug delivered major weight loss in a trial, but some patients stopped using it after losing too much weight.
www.statnews.comFindings demonstrated that participants with obesity lost more than 24% of their starting body weight within 48 weeks of treatment with the highest dose of retatrutide. Additionally, 100% of the participants taking either of the two higher doses (8 mg and 12 mg) lost at least 5% or more of their body weight. The results indicate that retatrutide has an overall safety and tolerability profile similar to other nutrient-stimulated hormone-based therapies, such as GLP-1 receptor agonists approved...
diabetes.org(UPDATED) The once-weekly injectable targeting three hormone receptors hints at “fundamental change” for cardiometabolic disease.
www.tctmd.com